Description
ARA-290 Research Overview
ARA-290 is a small peptide engineered from erythropoietin with a research profile distinct from conventional erythropoietin therapy. It was designed to investigate tissue-protective signaling without the erythropoietic activity associated with the parent hormone.
Research has extended from laboratory models into early human clinical studies, particularly involving neuropathic symptoms and tissue repair pathways.
How It Works
ARA-290 is designed to interact with the innate repair receptor, a signaling system associated with tissue protection and resolution of inflammatory responses. Research has examined how this pathway may influence nerve function, metabolic measures, and tissue recovery.
POTENTIAL RESEARCH INTEREST
- Neuropathy research: Clinical studies have examined ARA-290 in people with small-fiber neuropathy and reported improvements in selected neuropathic outcomes.
- Tissue-repair pathways: Its interaction with the innate repair receptor makes ARA-290 relevant to research into protective and regenerative signaling.
- Metabolic research: A Phase 2 study in people with type 2 diabetes reported changes in HbA1c and lipid measures alongside neuropathic outcomes.
- Neuroprotective research: ARA-290 has been investigated in models examining inflammatory and nerve-related tissue injury.
Dosage
Clinical investigations have used defined experimental dosing schedules, including 4 mg daily for 28 days in one Phase 2 study. These study parameters are research information and should not be treated as a general dosing recommendation.
Side Effects
Clinical studies reported no major safety signal within the investigated study periods, but this does not establish long-term safety or suitability outside controlled research.
Handling & Safety
Handle with standard laboratory precautions and avoid direct exposure. Researchers should follow institutional procedures for preparation, storage, and disposal.
Where to Buy ARA-290
IML does not directly market, manufacture, or fulfill ARA-290. Any external purchasing route is independent of IML’s editorial platform and should be evaluated for identity, quality documentation, and research-use requirements.
IML Affiliate Disclosure
IronMountainLabz may receive compensation when qualifying purchases are made through selected third-party links. The affiliate relationship does not make IML the seller or supplier of the referenced material.
References
- Brines M, et al. *ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.* Molecular Medicine. 2015;20:658–666. PMID: 25387363. PubMed reference
